Volume 83, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Complications of amphotericin B limit its wide application in the treatment of patients with kala-azar. This study was undertaken with an aim to minimize anti-renal complications and severe rigor in course of treatment with this drug. Parasitologically confirmed kala-azar cases (n = 230) were randomized equally into two groups: a control group received amphotericin B only at a dose of 1 mg/kg of body weight/day for 20 days and a patient (test) group received 500 mL of physiologic saline and 30 mL (60 meq/L) of KC1 with amphotericin B. We observed a significantly lower increase in serum creatinine levels ( = 0.0001) and a lower incidence of severe rigor and fever ( = 0.0165) in the test group than in the control group. However, the ultimate cure rate was not significantly different ( = 0.5637) between two groups after 12 months of follow-up. Relapses occurred after even after six months in both groups. Persons with relapses were treated with 25 infusions of amphotericin B and cured. Supplementation of amphotericin B with 500 mL of physiologic saline and 30 mL (60 meq/L) of KCl during treatment could help prevent an increase in serum creatinine levels and severe rigor and would make the treatment of kala-azar with amphotericin B easier.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Prata A, , 1963. Treatment of kala-azar with amphotericin B. Trans R Soc Trop Med Hyg 57: 266268.[Crossref] [Google Scholar]
  2. Thakur CP, Kumar S, , 1993. Diminishing effectiveness of currently used drugs in treatment of kala-azar and amphotericin B in antimony and pentamidine resistant kala-azar. , ed. Current Trends in Leishmania Research. New Delhi, India: Council of Scientific and Industrial Research, India: 254262. [Google Scholar]
  3. Mishra M, Singh MP, Choudhury D, Singh VP, Khan AP, , 1991. Amphotericin B for second line treatment of Indian kala-azar. Lancet 337: 926.[Crossref] [Google Scholar]
  4. Lira R, Sundar S, Makharia A, Keeny R, Gam A, Saraiva E, Sack D, , 1999. Evidence that the high incidence of treatment failure in kala-azar is due to the emergence of antimony resistant strains of Leshmania donovani . J Infect Dis 180: 564567.[Crossref] [Google Scholar]
  5. Thakur CP, Sinha SP, Sharma V, Pandey AK, Kumar M, Verma BB, , 1993. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian J Med Res 97: 170175. [Google Scholar]
  6. Thakur CP, Kumar A, Mitra G, Thakur S, Sinha PK, Das P, Bhattacharya SK, Sinha A, , 2008. Impact of amphotericin B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J Med Res 128: 5864. [Google Scholar]
  7. Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, Rahman M, Kar S, Goswami R, Guha SK, Pramanik N, Saha B, Ali N, , 2007. IL-10- and TGF-β-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol 179: 55925603.[Crossref] [Google Scholar]
  8. Gallis HA, Drew RH, Pickard WW, , 1990. Amphotericin B. 30 years of clinical experience. Rev Infect Dis 12: 308329.[Crossref] [Google Scholar]
  9. Bindschadler DD, Bennett JE, , 1969. A pharmacological guide to the clinical use of amphotericin B. J Infect Dis 120: 427436.[Crossref] [Google Scholar]
  10. Khoo SH, Bond J, Denning DW, , 1994. Administering amphotericin B – a practical approach. J Antimicrob Chemother 33: 203213.[Crossref] [Google Scholar]
  11. Thakur CP, , 1995. Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration. Natl Med J India 8: 1314. [Google Scholar]
  12. Thakur CP, , 1998. Sodium antimony gluconate, amphotericin, and myocardial damage. Lancet 27: 19281929.[Crossref] [Google Scholar]
  13. Nuzum E, White F III, Thakur CP, Dietze R, Wages J, Grogl M, Berman J, , 1995. Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood. J Infect Dis 171: 751754.[Crossref] [Google Scholar]
  14. Thakur CP, Sinha GP, Pandey AK, , 1996. Comparison of regimens of amphotericin B deoxycholate in kala-azar. Indian J Med Res 103: 259263. [Google Scholar]
  15. Jha TK, Giri YN, Singh TK, Jha S, , 1995. Use of amphotericin in drug resistant cases of visceral leishmaniasis in North Bihar, India. Am J Trop Med Hyg 52: 336538. [Google Scholar]
  16. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A, , 1999. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 93: 319323.[Crossref] [Google Scholar]
  17. Bhattacharya SK, Sinha PK, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK, , 2007. Phase-4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 196: 591598.[Crossref] [Google Scholar]
  18. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, , 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 25712581.[Crossref] [Google Scholar]
  19. Fisher Exact Test, 1998. Available at: http://hedwig.mgh.harvard.edu/sample_size/fisher/fishapp.html.
  20. Medical Journal of Australia, 2002. Determining the Sample Size in a Clinical Trial. Available at: http://www.mja.com.au/public/issues/177_05_020902/kir10425_fm.html. [Google Scholar]
  21. Chulay JD, Bryceson AD, , 1983. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 32: 475479. [Google Scholar]
  22. Cancer Therapy Evaluation Program, Common Toxicity Criteria. Rockville, MD: National Cancer Institute, 2002. Available at: http://ctep.cancer.gov/reporting/index.html Accessed December 7, 2003. [Google Scholar]
  23. Sundar R, Rai M, , 2002. Advances in the treatment of visceral leishmaniasis. Curr Opin Infect Dis 15: 593598.[Crossref] [Google Scholar]
  24. Sundar S, Chatterjee M, , 2006. Visceral leishmaniasis—current therapeutic modalities. Indian J Med Res 123: 345352. [Google Scholar]
  25. Bailey JE, Meyers C, Keigman RM, , 1990. Pharmacokinetics; outcome of treatment and toxic effects of amphotericin B and 5 flucytosine in neonates. J Pediatr 116: 791.[Crossref] [Google Scholar]
  26. Amphotericin B, 2009. Available at: http://www.google.co.in/search9hl=en&source=hp&q=amphotericin+B+&meta=saq=f408/26/2009.
  27. Ramakant B, , Kala-Azar Patients Lack Adequate Diagnosis and Drug. February 5th, 2009 - 8:59 pm ICT by admin. Available at: http://www.thaindian.com/newsportal/health/kala-azar-patients-lack-adequate-diagnosis-and-drugs_10015619.html. [Google Scholar]
  28. Thakur CP, , 2007. A new strategy for elimination of kala-azar from rural Bihar. Indian J Med Res 126: 447451. [Google Scholar]

Data & Media loading...

  • Received : 04 May 2010
  • Accepted : 22 Jul 2010
  • Published online : 05 Nov 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error